Confluence Investment Management LLC lifted its position in shares of Innophos Holdings, Inc. (NASDAQ:IPHS) by 3.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 96,576 shares of the specialty chemicals company’s stock after acquiring an additional 3,082 shares during the quarter. Confluence Investment Management LLC owned approximately 0.49% of Innophos worth $4,513,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Deprince Race & Zollo Inc. bought a new stake in Innophos in the 3rd quarter valued at about $10,358,000. Daruma Capital Management LLC increased its position in Innophos by 15.5% in the 2nd quarter. Daruma Capital Management LLC now owns 1,182,095 shares of the specialty chemicals company’s stock valued at $51,823,000 after buying an additional 158,861 shares in the last quarter. Goldman Sachs Group Inc. increased its position in Innophos by 58.1% in the 2nd quarter. Goldman Sachs Group Inc. now owns 321,140 shares of the specialty chemicals company’s stock valued at $14,079,000 after buying an additional 118,043 shares in the last quarter. BlackRock Inc. increased its position in Innophos by 3.8% in the 2nd quarter. BlackRock Inc. now owns 2,432,009 shares of the specialty chemicals company’s stock valued at $106,620,000 after buying an additional 89,360 shares in the last quarter. Finally, Segall Bryant & Hamill LLC increased its position in Innophos by 11.0% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 820,518 shares of the specialty chemicals company’s stock valued at $40,361,000 after buying an additional 81,550 shares in the last quarter. 94.46% of the stock is currently owned by hedge funds and other institutional investors.
IPHS has been the topic of a number of research analyst reports. Zacks Investment Research cut shares of Innophos from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 4th. KeyCorp reissued a “hold” rating on shares of Innophos in a report on Wednesday, November 1st. Finally, BidaskClub cut shares of Innophos from a “hold” rating to a “sell” rating in a report on Tuesday, December 5th.
Innophos (NASDAQ:IPHS) last posted its earnings results on Tuesday, October 31st. The specialty chemicals company reported $0.78 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.72 by $0.06. Innophos had a net margin of 6.19% and a return on equity of 13.90%. The company had revenue of $184.00 million during the quarter, compared to analyst estimates of $179.33 million. During the same period in the prior year, the business posted $0.69 earnings per share. Innophos’s revenue for the quarter was down 1.1% on a year-over-year basis. equities analysts forecast that Innophos Holdings, Inc. will post 2.5 EPS for the current year.
WARNING: “Confluence Investment Management LLC Has $4.51 Million Position in Innophos Holdings, Inc. (IPHS)” was reported by BBNS and is owned by of BBNS. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://baseballnewssource.com/markets/confluence-investment-management-llc-buys-3082-shares-of-innophos-holdings-inc-iphs/1822466.html.
Innophos Holdings, Inc is a producer of nutritional specialty ingredients with applications in food, beverage, dietary supplements, pharmaceutical, oral care and industrial end markets. The Company also provides bioactive mineral and nutritional ingredients. The Company’s segments include Specialty Phosphates US & Canada, Specialty Phosphates Mexico, and Granular Triple Super Phosphate (GTSP) & Other.
Receive News & Ratings for Innophos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innophos and related companies with MarketBeat.com's FREE daily email newsletter.